CNC Centene Corporation
XNYS
70.24
Delayed
Stock quote, options chain, IV rank, technicals, AI analysis, and institutional ownership. Iron condor setups Expected move IV rank history Fibonacci levels Insider trading
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
CNC
$70.24
—
Key stats
$70.24
- 52-Week Range
- $31.63 – $71.71
- YTD
- +68.12%
- IV Rank (30D)
- 59.37
- Straddle Price
- $8.38
- P/C Vol Ratio
- 0.86
- Market Cap
- $35.0B
- Open
- $70.90
- Day Range
- $69.63 – $71.71
- Volume
- 3,048,600
- Prev Close
- $70.81
Fair Value
+50.0% vs price
A blended fair-value estimate combining up to six valuation methods. Each method is weighted by how well it fits the company — DCF down-weights for unprofitable names; DDM only fires for steady dividend payers; comparables down-weight when peer multiples disagree.
- DCF (quality-aware) — projects free cash flow with a horizon that scales to business quality. True compounders (quality 6/6) get 10 years explicit + 10 years fade before terminal; cyclical/struggling names (quality 0-1) get a 5-year terminal cliff. Quality is scored from ROE, gross margin, growth, FCF margin, debt load, and FCF consistency — the same factors that drive market premium for compounders.
- Market-Implied Growth (in Model Inputs) — reverse-DCF that answers "what growth rate is the market pricing in?". Lets you sanity-check the deviation: if implied growth is plausible for the business, the model's bearish flag may be wrong; if implausible, the market may be over-extrapolating.
- DDM (Gordon Growth Dividend Model) — values the stream of future dividends. Only used when trailing yield ≥ 2% and dividend payments are stable — below that the dividend is a token payout and Gordon (which values only the dividend stream) systematically underprices growth names, so those route to DCF + comparables + market anchor instead.
- P/E, EV/EBITDA, P/B, P/S — applies the peer-group median multiple to this company's per-share metric. Peers come from the same set as the "Related symbols" card. Earnings/sales metrics are forward-tilted by the company's recent revenue growth (capped at 25%) so they're comparable to peers' growth-embedded multiples — mimics how analysts use NTM rather than TTM. Per-multiple weights are biased by company quality (e.g. P/B down-weighted for asset-light tech).
- Market Anchor (SMA50) — the 50-day moving average, weighted by recent trading-range stability (tighter Bollinger bands → higher weight). Captures information fundamentals miss (forward consensus, sentiment, supply/demand) — but only when recent trading is steady enough that the market has converged on a view. During wild breakouts or breakdowns the anchor's weight collapses.
- Options Expected (B-L 30d) — the risk-neutral expected stock price at 30-day options expiration, derived from the full implied-volatility surface via Breeden-Litzenberger (second derivative of call price wrt strike → implied PDF, then E[S_T]). Forward-looking, captures all options-implied information (smile, skew, term structure) in one number. Weighted by chain liquidity. SP500-only at present (pre-computed daily). Backtest evidence: adds modest alpha across most bucket × holding combos.
- Blended value — weighted average. Confidence reflects how many methods fired and how tight peer dispersion is.
- Deviation pill — green when blended FV ≥ 10% above current price (undervalued); red when ≥ 10% below; grey otherwise.
| 10-yr Treasury (rf) | 5.09% |
| Beta vs SPY | 0.67 |
| Cost of Equity (CAPM) | 8.45% (VRP-adj) |
| WACC | 7.49% |
| Volatility Risk Premium | +22.2pp (IV − HV30) |
| Effective Tax Rate | 21.0% |
| Rev. Growth (YoY, DCF input) | +2.5% |
| DCF Horizon | 5 years explicit + fade |
| Forward Tilt (NTM/TTM) | ×1.03 (applied to P/E, EV/EBITDA, P/S) |
| Free Cash Flow (TTM) | $9.0B |
| Return on Equity (TTM) | -22.6% |
| Book / Price | 61.6% — banking bias active (P/B is primary) |
| Gross Margin (TTM) | 20.1% |
| FCF Margin (TTM) | 4.5% |
| Debt / Equity | 0.76 |
| Quality Score | 1/6 — cyclical/struggling (5y DCF) |
| SMA 50 | $65.54 (Market Anchor value) |
| SMA 20 / Bollinger Mid | $65.28 |
| Bollinger Width / SMA20 | 30.4% (drives anchor stability) |
| Net Debt | $-4.9B |
| Market Cap | $35B |
Peers used for multiples: CI, ELV, HUM, UNH
(filtered from 8 ETF-co-members; sector bias active)
Blended Fair Value
$194.98
Deviation
+50.0%
| Method | Implied Price | Weight | Detail |
|---|---|---|---|
| DCF | $383.26 | 36% | |
| DDM (Gordon) | n/a | 0% | |
| Peer P/E | n/a | 0% | median 22.3× · 4 peers |
| Peer EV/EBITDA | $97.86 | 5% | median 14.7× · 4 peers |
| Peer P/B | $101.89 | 16% | median 2.3× · 4 peers |
| Peer P/S | $165.99 | 5% | median 0.4× · 4 peers |
| Market Anchor (SMA50) | $65.54 | 0% | stability 0% (BB-width) |
| Options Expected (B-L 30d) | $67.50 | 36% | 30 strikes · skew -0.45 |
As of 2026-10-21 · updated
Related
About
- Industry (SIC)
- HOSPITAL & MEDICAL SERVICE PLANS (6324) · industry map
- Exchange
- XNYS
- Market Cap
- $35.0B
- Employees
- 61,100
- List Date
- 2001-12-13
- CIK
- 0001071739
- Next Earnings
- 2026-10-27 (Pre-Market)
- EPS Forecast
- $0.07 (6 est.)
- Headquarters
- St Louis, MO
- Homepage
- https://www.centene.com
Centene is a managed care organization that focuses on government-sponsored healthcare plans, including Medicaid, Medicare, and the individual exchanges. Centene served 20 million medical members as of December 2025, mostly in Medicaid (about 64% of membership), the individual exchanges (about 28%), and Medicare (about 5%). The company also provides Medicare Part D pharmaceutical plans.
Summary
—
composite
—
No summary data available for this symbol yet.
Each spoke is this symbol's rank within its sector (0–100; the dotted ring marks the sector median at 50). Higher is more constructive for a long. One spoke — News sentiment — is an absolute reading, not a sector rank. Grayed spokes have no data. A fuller shape is a summary, not a recommendation.
Chart
Seasonality
| Month | '21 | '22 | '23 | '24 | '25 | '26 | Avg |
|---|---|---|---|---|---|---|---|
| Jan | -2.88% | -5.92% | -4.39% | -1.98% | 5.82% | 3.69% | -0.94% |
| Feb | -1.78% | 7.37% | -8.97% | 4.16% | -10.27% | 4.86% | -0.77% |
| Mar | 7.61% | 1.25% | -7.74% | 0.64% | 3.62% | -26.59% | -3.54% |
| Apr | -2.39% | -5.80% | 6.59% | -6.03% | -0.99% | 58.14% | 8.25% |
| May | 17.91% | 3.01% | -9.04% | -0.91% | -5.00% | 11.74% | 2.95% |
| Jun | -0.48% | 4.19% | 3.87% | -6.79% | -1.15% | 3.53% | 0.53% |
| Jul | -6.86% | 7.84% | 1.07% | 17.72% | -53.98% | -8.42% | -7.10% |
| Aug | -10.43% | -2.72% | -9.35% | 1.18% | 12.08% | 0.91% | -1.39% |
| Sep | -0.64% | -14.72% | 12.42% | -6.17% | 20.46% | -4.77% | 1.10% |
| Oct | 12.99% | 6.41% | -0.46% | -15.80% | -1.04% | 15.17%* | 2.88% |
| Nov | -0.46% | 1.30% | 6.29% | -5.54% | 14.03% | -- | 3.12% |
| Dec | 17.41% | -4.43% | -0.89% | 0.87% | 8.60% | -- | 4.31% |
| Total | 28.70% | -4.70% | -12.66% | -20.04% | -30.34% | 48.00% | 1.49% |
Technical Indicators
Quick-reference for reading the values below. Indicators combine to confirm a view — no single one is a trade signal on its own.
Trend Indicators
- SMA 20 / 50 / 200 — price above = uptrend, below = downtrend. SMA 50 crossing SMA 200 is the golden/death cross.
- EMA 12 / 26 — faster-reacting averages; 12 above 26 is short-term bullish.
- MACD — bullish when MACD > signal (green badge), bearish when below. Divergence from price often precedes reversals.
- ADX (14) — trend strength regardless of direction. <20 range, 20–25 weak trend, 25–50 trend, >50 strong trend.
- +DI / −DI — +DI > −DI favors bulls; the reverse favors bears. Read alongside ADX.
Momentum Oscillators
- RSI (14) — <30 oversold, >70 overbought. 40–60 is neutral; trending names can stay extreme.
- Stochastic %K / %D — <20 oversold, >80 overbought. %K crossing %D is an early momentum signal.
- Williams %R — inverted scale: <−80 oversold, >−20 overbought.
Oscillators work best in range-bound markets; in strong trends they give premature reversal signals.
Volume & Volatility
- Bollinger Bands — price at upper band = overbought, lower = oversold. Narrow bands (squeeze) often precede expansion.
- OBV — cumulative volume; rising OBV confirms uptrend, falling OBV confirms downtrend. Divergence from price is a warning.
- Vol SMA 20 / Vol ROC — today's volume vs. 20-day average. Positive ROC with price move = conviction.
- ATR / True Range — average daily $ move; sizing and stop-loss reference.
- HV 20 / 30 / 60 — realized (historical) volatility. Compare to IV on the options cards: IV > HV = rich premium.
Confluence matters: trend + momentum + volume agreeing carries far more weight than any single indicator. For how these feed the spread scanner score, see the algorithm docs →
Trend Indicators
SMA 20: $65.69
SMA 50: $65.64
SMA 200: $54.55
Current: $70.24
EMA 12: $68.19
EMA 26: $66.69
MACD: 1.5041 | Signal: 0.6244
BULLISH
ADX (14): 17.36
RANGE
+DI: 26.62
−DI: 17.15
Momentum Oscillators
RSI (14): 63.26
NEUTRAL
Stoch %K: 87.08
Stoch %D: 86.08
Williams %R: -13.41
Volume & Volatility
BB Upper: $72.34
BB Lower: $59.04
NEUTRAL
OBV: -11,757,835
Vol SMA 20: 4,095,955
Vol ROC: -41.58%
ATR: $2.19
True Range: $2.08
HV 20: 24.9%
HV 30: 31.3%
HV 60: 33.9%
Data Summary
Data Points: 500
Last Updated:
Date Range: 2024-10-23T00:00:00 – 2026-10-21T00:00:00
AI Analysis
LLM Stock Analysis Report
System Prompt: You are a professional financial analyst providing comprehensive stock analysis reports.
Executive Summary
Overall Assessment: NEUTRAL (6/10)
Key Drivers:
- Technical indicators suggest a neutral trend with a potential upward bias.
- Recent news sentiment is mixed, with some negative headlines and positive earnings reports.
- Options market signals indicate low volatility with a moderate price movement expectation.
Primary Risks:
- Potential for a pullback if the stock fails to break above the upper Bollinger Band ($69.76).
- Risk of increased volatility if the stock's beta increases above 0.5.
Investment Thesis: The stock is expected to consolidate within its current trading range, with a potential upward bias due to its low volatility and neutral technical indicators. However, recent news sentiment is mixed, which may impact the stock's price movement in the short term.
Recent News Sentiment Impact:
- The negative headlines on Centene's membership slump have had a significant impact on the stock's price, contributing to the overall bearish tone.
- Positive earnings reports and general market commentary have helped alleviate some of the negativity, but have not been enough to drive a sustained upward move.
Technical Analysis
Trend Direction: NEUTRAL (Short-term: Neutral, Medium-term: Neutral, Long-term: Uptrend)
Support/Resistance Levels:
- Lower Bollinger Band ($60.99): Strong support level.
- Upper Bollinger Band ($69.76): Key resistance level.
- SMA 20 ($65.38): Support level.
Momentum Signals:
- RSI (14) = 44.20: Neutral reading.
- MACD Signal Line Crossover: Bullish signal.
- Bollinger Bands Position: Neutral, indicating a lack of strong momentum.
Volume Analysis:
- Volume trend is neutral, with no clear indication of institutional interest or volume surges.
- OBV and On-Balance Volume (OBV) are both negative, suggesting selling pressure.
News & Sentiment Analysis
Recent Headlines Summary:
- Two negative headlines on Centene's membership slump and a general market downturn.
- One positive headline on earnings reports and one neutral headline on healthcare transportation services.
Sentiment Assessment: NEUTRAL (Negative 2, Positive 1, Neutral 1)
Catalyst Identification:
- Upcoming earnings reports may have an impact on the stock's price movement.
- Regulatory changes in the healthcare sector could also influence the stock's performance.
Market Narrative:
- The market is currently experiencing a mix of negative and positive headlines, which is reflected in the stock's neutral trend.
Risk & Volatility Assessment
Beta Interpretation: LOW (0.33 vs SPY) - indicating low risk relative to the broader market.
Volatility Regime: CURRENT VOLATILITY IS LOW (0.49)
Options Market Signals:
- IV Rank = 14.9% (Low) - indicates historically low volatility.
- Current IV = 50.4% - moderate price movement expectation.
Downside Protection:
- Support levels are in place, including the lower Bollinger Band ($60.99).
- Risk management considerations: Stop-loss levels should be set at $59.19 or lower to mitigate potential losses.
Market Context & Positioning
Sector Performance: HEALTHCARE SECTOR IS TRADING NEAR ITS 50-DAY MOVING AVERAGE, WITH MIXED PERFORMANCE AMONG PEERS.
Institutional Activity:
- Volume patterns suggest institutional interest is neutral.
- OBV and On-Balance Volume (OBV) are both negative, indicating selling pressure.
Correlation Analysis: STOCK HAS A NEGATIVE CORRELATION COEFFICIENT (-0.09) WITH THE SPY INDEX, INDICATING IT TENDS TO MOVE IN THE OPPOSITE DIRECTION OF THE MARKET.
Relative Valuation:
- Stock is trading within its historical trading range.
- Positioning relative to the market suggests a slightly defensive posture.
Key Levels & Action Items
Critical Price Levels:
- Lower Bollinger Band ($60.99): Strong support level.
- Upper Bollinger Band ($69.76): Key resistance level.
Breakout/Breakdown Levels:
- $63.61: SMA 50 - potential support level.
- $65.38: SMA 20 - potential support level.
Time-Sensitive Catalysts:
- Upcoming earnings reports may have an impact on the stock's price movement.
- Regulatory changes in the healthcare sector could also influence the stock's performance.
Risk Management:
- Stop-loss levels should be set at $59.19 or lower to mitigate potential losses.
- Position sizing considerations: Reduce position size if the stock breaks below its SMA 20 or declines by more than 5% in a single trading session.
Generated
News
All CNC news →
Earnings History
16 of 23 under expected move
Avg Expected Move
6.23%
Avg Actual Move
4.91%
| Earnings Date | Timing | Expected Move | Actual Move | Ratio | Outcome |
|---|---|---|---|---|---|
| 2021-02-09 | Pre-Market | 5.27% | 3.49% | 0.66x | Within |
| 2021-04-27 | Pre-Market | 3.98% | 7.11% | 1.79x | Exceeded |
| 2021-07-27 | Pre-Market | 4.25% | 3.03% | 0.71x | Within |
| 2021-10-26 | Pre-Market | 5.30% | 4.41% | 0.83x | Within |
| 2022-02-08 | Pre-Market | 5.87% | 6.04% | 1.03x | Exceeded |
| 2022-04-26 | Pre-Market | 4.90% | 3.51% | 0.72x | Within |
| 2022-07-26 | Pre-Market | 4.32% | 1.33% | 0.31x | Within |
| 2022-10-25 | Pre-Market | 4.62% | 10.32% | 2.23x | Exceeded |
| 2023-02-07 | Pre-Market | 4.08% | 0.04% | 0.01x | Within |
| 2023-04-25 | Pre-Market | 5.76% | 2.41% | 0.42x | Within |
| 2023-07-28 | Pre-Market | 4.55% | 5.39% | 1.18x | Exceeded |
| 2023-10-24 | Pre-Market | 4.32% | 1.65% | 0.38x | Within |
| 2024-02-06 | Pre-Market | 5.17% | 1.15% | 0.22x | Within |
| 2024-04-26 | Pre-Market | 3.30% | 2.22% | 0.67x | Within |
| 2024-07-26 | Pre-Market | 5.45% | 8.46% | 1.55x | Exceeded |
| 2024-10-25 | Pre-Market | 7.22% | 4.22% | 0.58x | Within |
| 2025-02-04 | Pre-Market | 7.17% | 5.45% | 0.76x | Within |
| 2025-04-25 | Pre-Market | 6.41% | 6.32% | 0.99x | Within |
| 2025-07-25 | Pre-Market | 8.50% | 6.09% | 0.72x | Within |
| 2025-10-29 | Pre-Market | 11.37% | 12.50% | 1.10x | Exceeded |
| 2026-02-06 | Pre-Market | 11.70% | 3.66% | 0.31x | Within |
| 2026-04-28 | Pre-Market | 10.05% | 13.95% | 1.39x | Exceeded |
| 2026-07-28 | Pre-Market | 9.63% | 0.27% | 0.03x | Within |
Earnings calendar: this week’s reports with expected vs actual moves →
CNC Options Activity & IV Rank
CNC IV rank history, 52-week IV rank and IV percentile →
Volatility Metrics
Current IV: 52.0%
7-DTE IV: 67.7%
Expected Move: $8.38
7-DTE Move: $6.10
Days to Exp: 30 (2026-11-20)
Options Flow
Call Volume: 315
Put Volume: 271
P/C Volume: 0.86
NEUTRAL
Call OI: 6,104
Put OI: 5,272
P/C OI: 0.864
Total OI: 11,376
ATM Options Pricing
ATM Call: $4.22
ATM Put: $4.15
Call %: 6.0%
Put %: 5.9%
Chain Summary
Chain Volume: 9,051
Chain OI: 211,917
Last Updated: 10/21/2026
Spread Scanner GPU
Each spread is ranked by a composite score built in three stages. Full documentation →
Stage 1 — Base Score (GPU scanner)
score = P(profit) × (credit / spread_width)
P(profit) from short leg delta (1 − |delta|), penalised above 85%. Credit uses mid-price to handle illiquid chains fairly.
Stage 2 — Skew Adjustment (±25% cap)
RR and BF (30-delta) from the persisted per-symbol skew snapshot — wing strikes picked by real greeks.delta, not a moneyness proxy. Put skew boosts bull puts, penalises bear calls. High butterfly boosts iron condors. Calendars are skew-neutral.
Stage 3 — Technical Overlay (±50% cap, 5 groups)
Group 1 · Directional Bias (±0.25)
- RSI <40 bullish / >60 bearish
- MACD crossover + histogram trend
- Price vs SMA 50 & SMA 200
Group 2 · Momentum (±0.10)
- Stochastic %K <20 / >80
- Williams %R <−80 / >−20
Group 3 · Volatility (up to −0.25 / +0.15)
- Blended ATR + straddle expected-move penalty
- Bollinger Band signal (+ counter-trend penalty)
- BB width — vol contraction boost for ICs
Group 4 · IV Regime (±0.15)
- IV rank ≥ 75 → strong boost for credit spreads
- IV rank < 25 → penalty (selling cheap vol)
Group 5 · Liquidity (penalty up to −0.10)
- Min open interest across all legs
- OI < 100 → −0.10 · OI < 500 → −0.05
score = base_score × skew_multiplier × tech_multiplier
Both multipliers are shown per spread. Beta is informational only — ATR already captures realized vol. Full algorithm documentation →
Enter a ticker to scan for optimal spread opportunities.
Evaluates all bull put, bear call, iron condor, and calendar spread combinations using GPU-accelerated analysis.
Dealer Positioning
HIGH γ vs HISTORY
Estimated net dealer gamma is at the 97th percentile of this name's own daily history, near the high end of its range. This describes current positioning; it is not a forecast or a trading signal.
Gamma percentile
97%
vs own history
GEX tilt
+0.62
OI-weighted, today
Vanna tilt
+0.31
δ-sensitivity to IV
Charm tilt
-0.32
δ-decay vs time
Vanna tilt +0.31: the estimated dealer exposure leans positive, so the modeled hedge would shift noticeably if implied volatility changed.
Charm tilt -0.32: the estimated dealer exposure leans negative, so the modeled hedge would shift noticeably as time passes and options approach expiry.
? What is this?
· 127 ATM contracts, 54k total OI
Net dealer gamma is an estimate of the aggregate gamma held by options market makers across this name's option chain, weighted by open interest. Dealer positions aren't public, so it uses a standard simplifying assumption: dealers are treated as long the calls and short the puts that are open. Actual dealer books can differ.
Gamma percentile ranks today's estimate against this name's own daily history, from 0% (the lowest reading on record) to 100% (the highest). Raw gamma scales with how much open interest a chain carries, so it isn't comparable across names; the percentile is. The badge marks the bottom 20% as low and the top 20% as high.
Tilts run from −1 to +1 and show how lopsided the estimated dealer exposure is. GEX tilt compares call gamma with put gamma. Vanna tilt describes how the hedge would shift if implied volatility changed, and charm tilt how it would shift with the passage of time.
This card describes estimated positioning and where it sits historically. It is not a forecast of price direction or volatility and not a trading signal. Market-wide view: Dealer positioning screener.
Skew (Wing IV − ATM IV)
DTE:
Wing Δ:
Wing vs ATM
IV(put wing) − IV(ATM), in vol pointsHow much the OTM put trades above (or below) the at-the-money strike. Measures the height of the put-side tail relative to ATM — i.e. how expensive crash insurance is on this name.
- Positive (typical) — wing IV > ATM IV. Standard equity put skew: portfolios bid up crash protection, so OTM puts trade richer than ATM.
- Near zero or negative (unusual) — wing IV ≤ ATM IV. Flat or inverted put side. Common when there's no fear demand, in tightly mean-reverting names, or right after an earnings catalyst clears.
- Percentile vs own 3-yr history: high = wings rich (good time to sell wing premium); low = wings cheap (good time to buy protection).
- Not directional — high or low wings don't predict up or down moves. It's a price tag on tail insurance, not a forecast.
Risk Reversal
IV(call wing) − IV(put wing), equal delta on each sideWhich side of the smile is the market paying up for? Measures the tilt of the surface — call skew vs put skew at matched deltas.
- Negative (typical) — puts richer than calls. Standard equity behavior: hedging demand makes puts carry a premium. Most large-caps sit in the −1 to −5 vol-point range.
- Strongly negative (< −5 pts) — heavy downside hedging, elevated fear, or an upcoming catalyst (earnings, FDA, macro event). Worth flagging.
- Positive — calls richer than puts. Unusual for equities; signals bullish momentum, short-squeeze positioning, or takeover/M&A speculation.
- Near zero — symmetric surface. Market sees roughly equal up/down risk. Rare for large-caps; more common in commodities and FX.
Reading them together
Wing-vs-ATM tells you how expensive the tails are. Risk Reversal tells you which side is favored. Combined:
- High wing percentile + deeply negative RR → strong put bid; stress or major event priced in. Owning protection costs a premium; selling put premium is dangerous.
- Low wing percentile + near-zero RR → complacency; insurance cheap and balanced. Good environment to add cheap downside hedges.
- Positive RR + elevated wings → call-side fear-of-missing-out; common in squeeze setups. Upside calls expensive, downside puts not bid.
14 DTE / 10d
47%
+5.7
pts
EXTREME
as of Oct 21 · ATM 56.6% / Wing 62.3%
30 DTE / 10d
29%
+3.9
pts
EXTREME
as of Oct 21 · ATM 52.3% / Wing 56.2%
Extreme reading.
Historically these have been contrarian — on the small set of observed earnings-day cases, large negative wing-vs-ATM gaps (calls pricing much richer than puts at the same delta) preceded sharp drops in the underlying within 1-12 days. Not financial advice and the dataset is small.
Percentile is the rank of today's reading within ~3 years of this symbol's own history. High percentile = wings are rich relative to history; not a directional signal. Skew is read off the chain in real time, not from CBOE SKEW.
Volatility Surface
Enter a ticker to render the implied volatility surface.
Volatility Smile
Enter a ticker to render the implied volatility smile.
IV Rank (7 DTE)57.5MediumOct 21
IV Rank (30 DTE)59.4MediumOct 21
Straddle Price (30 DTE)$8.38Oct 21
Beta Analysis
Risk Metrics
Beta: 0.3044
Alpha: 73.52%
Correlation: 0.0818
R-Squared: 0.7%
Stock Volatility: 47.3%
Market Volatility: 12.7%
Analysis Details
Benchmark: SPY
Data Points: 251
Period: 252 trading days
Data Points: 251
Period: 252 trading days
Interpretation:
Low volatility - stock moves less than market
Low volatility - stock moves less than market
Beta & Alpha Over Time
Notable investors who own CNC
7 of 37 tracked investors
| Investor | Value | Share of their portfolio | Rank | Q/Q shares | Source |
|---|---|---|---|---|---|
| Renaissance Technologies Hedge fund Jim Simons | $140.7M | #100 of 3138 | +30.1% | 13F | |
| Glenview Capital Hedge fund Larry Robbins | $121.1M | #13 of 42 | -41.3% | 13F | |
| Millennium Management Hedge fund Izzy Englander | $102.1M | #331 of 3716 | -38.6% | 13F | |
| Citadel Hedge fund Ken Griffin | $64.7M | #563 of 6285 | -42.0% | 13F | |
| Point72 Hedge fund Steve Cohen | $43.8M | #363 of 1945 | -72.0% | 13F | |
| Bridgewater Associates Hedge fund Ray Dalio | $24.9M | #167 of 997 | +130.3% | 13F | |
| Rockefeller Capital Management Family office Rockefeller family | $1.4M | #1527 of 4729 | -34.5% | 13F |
Hedge funds, activists, holding companies and family offices we track, from their latest 13F (quarter-end value) and Form 4 filings in the last 3 years. Family offices · all institutions
CNC Institutional Ownership (13F)
Latest filings — 2026-09-30
? 13F Guide
Diluted shares outstanding: 493,349,000 (as of 2026-03-31)
Institutional managers with $100M+ AUM file Form 13F-HR quarterly, due 45 days after quarter end. Holdings are reported gross at quarter-end market value — they are a snapshot, not a real-time position.
- Shares — long equity positions in this name, aggregated across share classes.
- Calls / Puts — notional value of long call / put exposure where this ticker is the underlying.
- % of Float — holder's reported shares divided by the latest diluted shares outstanding. Sums above 100% indicate large custodian / prime broker positions where the same shares are reported by multiple filers.
- Custodian badge — filers with more than 5,000 holdings are typically broker-dealers / custodians reporting customer-held shares, not active managers.
Each filer is counted once at its latest 13F-HR filing. New filings are ingested on a weekly cadence.
35 filers$903.46M notional
| # | Filer | Notional Value | % of Total | Period |
|---|---|---|---|---|
| 1 | Susquehanna International Group, LLP Custodian | $290.16M | 32.12% | 2026-06-30 |
| 2 | Jane Street Group, LLC Custodian | $150.24M | 16.63% | 2026-06-30 |
| 3 | Citadel Advisors LLC Custodian | $135.79M | 15.03% | 2026-06-30 |
| 4 | Walleye Trading LLC | $89.77M | 9.94% | 2026-06-30 |
| 5 | Millennium Management LLC Custodian | $36.94M | 4.09% | 2026-06-30 |
| 6 | D. E. Shaw & Co., Inc. Custodian | $22.49M | 2.49% | 2026-06-30 |
| 7 | Wolverine Trading, LLC Custodian | $22.30M | 2.47% | 2025-09-30 |
| 8 | Cubist Systematic Strategies, LLC | $18.06M | 2.00% | 2025-09-30 |
| 9 | Point72 Asset Management, L.P. | $17.65M | 1.95% | 2026-06-30 |
| 10 | CAPITAL FUND MANAGEMENT S.A. | $15.80M | 1.75% | 2026-06-30 |
| 11 | Caption Management, LLC | $14.24M | 1.58% | 2026-06-30 |
| 12 | Alphadyne Asset Management LP | $13.74M | 1.52% | 2026-06-30 |
| 13 | Goldman Sachs Group Inc Custodian | $12.84M | 1.42% | 2026-06-30 |
| 14 | Squarepoint Ops LLC | $11.88M | 1.32% | 2026-06-30 |
| 15 | UBS Group AG Custodian | $8.34M | 0.92% | 2026-06-30 |
| 16 | Parallax Volatility Advisers, L.P. | $8.02M | 0.89% | 2026-06-30 |
| 17 | Qube Research & Technologies Ltd | $5.88M | 0.65% | 2026-06-30 |
| 18 | Balyasny Asset Management L.P. | $5.42M | 0.60% | 2026-06-30 |
| 19 | Endure Capital Management, LLC | $4.33M | 0.48% | 2026-06-30 |
| 20 | NOMURA HOLDINGS INC | $2.95M | 0.33% | 2026-06-30 |
| 21 | Citigroup Inc. Custodian | $2.50M | 0.28% | 2026-06-30 |
| 22 | Walleye Capital LLC | $2.25M | 0.25% | 2026-06-30 |
| 23 | TUDOR INVESTMENT CORP ET AL | $1.78M | 0.20% | 2026-06-30 |
| 24 | Tidal Investments LLC | $1.73M | 0.19% | 2026-06-30 |
| 25 | Brevan Howard Capital Management LP | $1.65M | 0.18% | 2026-06-30 |
29 filers$523.91M notional
| # | Filer | Notional Value | % of Total | Period |
|---|---|---|---|---|
| 1 | Bank of Montreal Custodian | $75.73M | 14.46% | 2026-06-30 |
| 2 | Susquehanna International Group, LLP Custodian | $65.01M | 12.41% | 2026-06-30 |
| 3 | Jane Street Group, LLC Custodian | $58.47M | 11.16% | 2026-06-30 |
| 4 | Citadel Advisors LLC Custodian | $57.58M | 10.99% | 2026-06-30 |
| 5 | Walleye Trading LLC | $45.58M | 8.70% | 2026-06-30 |
| 6 | D. E. Shaw & Co., Inc. Custodian | $41.25M | 7.87% | 2026-06-30 |
| 7 | Cubist Systematic Strategies, LLC | $25.31M | 4.83% | 2025-09-30 |
| 8 | Goldman Sachs Group Inc Custodian | $20.10M | 3.84% | 2026-06-30 |
| 9 | Alphadyne Asset Management LP | $19.35M | 3.69% | 2026-06-30 |
| 10 | Squarepoint Ops LLC | $15.41M | 2.94% | 2026-06-30 |
| 11 | Davidson Kempner Capital Management LP | $15.41M | 2.94% | 2026-06-30 |
| 12 | Point72 Asset Management, L.P. | $13.24M | 2.53% | 2026-06-30 |
| 13 | Wolverine Trading, LLC Custodian | $11.23M | 2.14% | 2025-09-30 |
| 14 | UBS Group AG Custodian | $8.94M | 1.71% | 2026-06-30 |
| 15 | CAPITAL FUND MANAGEMENT S.A. | $8.00M | 1.53% | 2026-06-30 |
| 16 | Caption Management, LLC | $7.82M | 1.49% | 2026-06-30 |
| 17 | PFM Health Sciences, LP | $5.66M | 1.08% | 2026-06-30 |
| 18 | Millennium Management LLC Custodian | $5.01M | 0.96% | 2026-06-30 |
| 19 | Citigroup Inc. Custodian | $5.01M | 0.96% | 2026-06-30 |
| 20 | Qube Research & Technologies Ltd | $4.08M | 0.78% | 2026-06-30 |
| 21 | Walleye Capital LLC | $3.54M | 0.68% | 2026-06-30 |
| 22 | NOMURA HOLDINGS INC | $2.95M | 0.56% | 2026-06-30 |
| 23 | TUDOR INVESTMENT CORP ET AL | $2.51M | 0.48% | 2026-06-30 |
| 24 | Balyasny Asset Management L.P. | $1.80M | 0.34% | 2026-06-30 |
| 25 | CAPSTONE INVESTMENT ADVISORS, LLC | $1.69M | 0.32% | 2026-06-30 |
CNC Insider Trading (Form 4)
Latest: 2026-10-15Form 4 filings — insider beneficial-ownership changes by officers, directors, and 10%+ holders. Filed within 2 business days of transaction.
| Filed | Reporter | Role | Action | Shares | Avg Price | Net $ | Link |
|---|---|---|---|---|---|---|---|
| 2026-10-15 | Michael A Carson | Group President, Medicare&Spec | Tax (F) | −7,130 | $70.16 | -$500.2K | EDGAR |
| 2026-09-30 | Frederick H Eppinger | Director | Award (A) | +864 | — | EDGAR | |
| 2026-09-30 | Lauren M Tyler | Director | Award (A) | +482 | — | EDGAR | |
| 2026-09-30 | Christopher J Coughlin | Director | Award (A) | +583 | — | EDGAR | |
| 2026-09-30 | Kenneth Tanji | Director | Award (A) | +603 | — | EDGAR | |
| 2026-09-30 | Theodore R. Samuels II | Director | Award (A) | +583 | — | EDGAR | |
| 2026-09-16 | Theodore J Pienkos | Corporate Controller & CAO | Tax (F) | −1,092 | $69.41 | -$75.8K | EDGAR |
| 2026-08-27 | Christopher Koster | Secretary & General Counsel | Sell (S) | −56,500 | $66.90 | -$3.78M | EDGAR |
| 2026-08-19 | Christopher Koster | Secretary & General Counsel | Sell (S) | −47,603 | $65.36 | -$3.11M | EDGAR |
| 2026-07-28 | Paul J Diaz | Director | Award (A) | +2,771 | — | EDGAR | |
| 2026-07-20 | Lauren M Tyler | Director | Award (A) | +3,155 | — | EDGAR | |
| 2026-07-01 | Lauren M Tyler | Director | Award (A) | +61 | — | EDGAR | |
| 2026-07-01 | Christopher J Coughlin | Director | Award (A) | +562 | — | EDGAR | |
| 2026-07-01 | Frederick H Eppinger | Director | Award (A) | +833 | — | EDGAR | |
| 2026-07-01 | Theodore R. Samuels II | Director | Award (A) | +465 | — | EDGAR |
Codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (described in filing footnote — typically 401(k), trust, inheritance) · W = will/inheritance. Only P / S codes carry directional signal.
CNC Insider Holdings
9 insiders · @ $70.24
Officers, directors, and 10%+ owners who have filed a Form 4 in the past two years, ranked by current disclosed exposure (shares × today's price). Shares are direct + indirect (via trusts / LLCs / spouse). Excludes unvested RSU and option grants — those aren't beneficially owned until vest.
| # | Insider | Role | Shares | Disclosed Exposure | Lifetime OM Net | Filings | Last Filed |
|---|---|---|---|---|---|---|---|
| 1 | Frederick H Eppinger | Director | 370,401 | $26.02M | $0 | 3 | 2026-09-30 |
| 2 | Christopher Koster | Secretary & General Counsel | 248,953 | $17.49M | -$6.89M | 2 | 2026-08-27 |
| 3 | Michael A Carson | Group President, Medicare&Spec | 116,577 | $8.19M | $0 | 1 | 2026-10-15 |
| 4 | Theodore R. Samuels II | Director | 57,795 | $4.06M | $0 | 3 | 2026-09-30 |
| 5 | Christopher J Coughlin | Director | 49,347 | $3.47M | $0 | 3 | 2026-09-30 |
| 6 | Theodore J Pienkos | Corporate Controller & CAO | 28,751 | $2.02M | $0 | 1 | 2026-09-16 |
| 7 | Kenneth Tanji | Director | 13,093 | $919.7K | $0 | 3 | 2026-09-30 |
| 8 | Lauren M Tyler | Director | 3,698 | $259.7K | $0 | 3 | 2026-09-30 |
| 9 | Paul J Diaz | Director | 2,771 | $194.6K | $0 | 1 | 2026-07-28 |
Lifetime OM Net = signed sum of open-market buys (P) and sells (S) over their career; excludes grants, tax withholdings, and dispositions to issuer. A large negative number is normal for long-tenured executives — they've sold compensation grants over many years.
CNC Board & Officers
As of SEC filings through Oct 15, 2026Directors 12
- Frederick H Eppinger · since Apr 25, 2006
- Jessica L. Blume · since Feb 5, 2018
- H James Dallas · on file since Jan 2020
- Sarah London · listed since Sep 2021
- Christopher J Coughlin · since Jan 5, 2022
- Theodore R. Samuels II · since Jan 5, 2022
- Kenneth A Burdick · listed since Jan 2022
- Monte E Ford · since Nov 12, 2022
- Thomas Greco · since Aug 9, 2024
- Kenneth Tanji · since Feb 20, 2025
- Lauren M Tyler · since Jun 19, 2026
- Paul J Diaz · since Jul 28, 2026
Officers 7
- Daniel P Finke · Group President, Markets&Comm · since May 12, 2026
- Michael A Carson · Group President, Medicare&Spec · since May 12, 2026
- Andrew Lynn Asher · Chief Financial Officer · listed since Mar 2024
- Susan Raye Smith · Chief Operating Officer · since Jan 1, 2024
- Tanya M McNally · Chief People Officer · since Feb 10, 2025
- Christopher Koster · Secretary & General Counsel · listed since Mar 2024
- Theodore J Pienkos · Corporate Controller & CAO · since Mar 18, 2026
Changes in the last 10 years (68)
| Jul 28, 2026 | Paul J Diaz became a director |
| Jun 19, 2026 | Lauren M Tyler became a director |
| May 12, 2026 | Michael A Carson became Group President, Medicare&Spec |
| May 12, 2026 | Daniel P Finke became Group President, Markets&Comm |
| Mar 18, 2026 | Theodore J Pienkos became Corporate Controller & CAO |
| Aug 1, 2025 | The company announced the departure of Wayne S DeVeydt from the board in an SEC filing |
| Feb 20, 2025 | Kenneth Tanji became a director |
| Feb 10, 2025 | Tanya M McNally became Chief People Officer |
| Nov 8, 2024 | The company announced the departure of Kenneth J Fasola as President in an SEC filing |
| Sep 25, 2024 | The company announced the departure of Lori Jean Robinson from the board in an SEC filing |
| Aug 9, 2024 | Thomas Greco became a director |
| Mar 19, 2024 | Katie Casso listed as Corporate Controller & CAO (previously SVP, Corporate Controller, CAO) in SEC filings |
| Mar 19, 2024 | Christopher Koster listed as Secretary & General Counsel (previously EVP, Secr. & General Counsel) in SEC filings |
| Mar 19, 2024 | Andrew Lynn Asher listed as Chief Financial Officer (previously EVP, CFO) in SEC filings |
| Jan 1, 2024 | Susan Raye Smith became Chief Operating Officer |
| Oct 10, 2023 | David P Thomas listed as CEO, Markets and Medicaid (previously EVP, Markets) in SEC filings |
| May 19, 2023 | The company announced the departure of Sarah London as Chief Executive Officer in an SEC filing |
| May 19, 2023 | The company announced the departure of James E Murray as EVP, Chief Operating Officer in an SEC filing |
| Jan 10, 2023 | James E Murray listed as EVP, Chief Operating Officer (previously EVP, Chief Transform. Officer) in SEC filings |
| Dec 28, 2022 | Kenneth J Fasola listed as President (previously EVP, Health Care Enterprises) in SEC filings |
| Dec 13, 2022 | The company announced the departure of Brent D Layton as President & COO in an SEC filing |
| Nov 12, 2022 | Monte E Ford became a director |
| Sep 28, 2022 | Kenneth J Fasola became EVP, Health Care Enterprises |
| Sep 28, 2022 | James E Murray became EVP, Chief Transform. Officer |
| Apr 11, 2022 | The company announced the departure of Leslie V Norwalk from the board in an SEC filing |
| Mar 31, 2022 | Sarah London listed as Chief Executive Officer (previously Vice Chairman) in SEC filings |
| Mar 15, 2022 | Katie Casso listed as SVP, Corporate Controller, CAO (previously SVP & Corporate Controller) in SEC filings |
| Feb 23, 2022 | Shannon Bagley became EVP, Chief Admin. Officer |
| Jan 14, 2022 | Kenneth A Burdick first listed as a director in an SEC filing |
| Jan 11, 2022 | Leslie V Norwalk became a director |
| Jan 5, 2022 | Wayne S DeVeydt became a director |
| Jan 5, 2022 | Theodore R. Samuels II became a director |
| Jan 5, 2022 | Christopher J Coughlin became a director |
| Dec 17, 2021 | Christopher Koster listed as EVP, Secr. & General Counsel (previously SVP, Secr. & General Counsel) in SEC filings |
| Dec 14, 2021 | The company announced the departure of Michael F Neidorff as Chairman & CEO in an SEC filing |
| Dec 14, 2021 | The company announced the departure of Kenneth A Burdick as EVP, Markets & Products in an SEC filing |
| Dec 14, 2021 | Brandy Burkhalter listed as EVP (previously EVP, Chief Operating Officer) in SEC filings |
| Nov 1, 2021 | Michael F Neidorff listed as Chairman & CEO (previously Chairman, President & CEO) in SEC filings |
| Oct 26, 2021 | The company announced the departure of Jesse N Hunter as EVP, M&A & Chief Strategy Ofcr in an SEC filing |
| Sep 9, 2021 | Sarah London listed as Vice Chairman (previously Pres. HCE & EVP, Adv. Tech.) in SEC filings |
| Sep 9, 2021 | Sarah London first listed as a director in an SEC filing |
| Sep 9, 2021 | Brent D Layton listed as President & COO (previously EVP, Pres. HP, Products & Intl) in SEC filings |
| Jul 27, 2021 | Colin A Toney became EVP, Mergers & Acquisitions |
| Jun 25, 2021 | Brent D Layton listed as EVP, Pres. HP, Products & Intl (previously EVP, Chief BD Officer) in SEC filings |
| May 7, 2021 | Andrew Lynn Asher became EVP, CFO |
| Apr 1, 2021 | Katie Casso became SVP & Corporate Controller |
| Mar 1, 2021 | Sarah London listed as Pres. HCE & EVP, Adv. Tech. (previously SVP, Technology & Innovation) in SEC filings |
| Feb 8, 2021 | Sarah London became SVP, Technology & Innovation |
| Feb 8, 2021 | Brent D Layton became EVP, Chief BD Officer |
| Mar 26, 2020 | Brandy Burkhalter listed as EVP, Chief Operating Officer (previously EVP, Operations) in SEC filings |
| Feb 21, 2020 | Christopher Koster listed as SVP, Secr. & General Counsel (previously Senior Vice President) in SEC filings |
| Feb 4, 2020 | Christopher Koster became Senior Vice President |
| Jan 27, 2020 | William L Trubeck first on file as a director |
| Jan 27, 2020 | Kenneth A Burdick first on file as EVP, Markets & Products |
| Jan 27, 2020 | H James Dallas first on file as a director |
| Nov 19, 2019 | Michael F Neidorff listed as Chairman, President & CEO (previously Chairman & CEO) in SEC filings |
| Oct 22, 2019 | Lori Jean Robinson became a director |
| Oct 22, 2019 | David P Thomas became EVP, Markets |
| Dec 14, 2018 | Jesse N Hunter listed as EVP, M&A & Chief Strategy Ofcr (previously EVP & Chief Strategy Officer) in SEC filings |
| Dec 14, 2018 | Cynthia J Brinkley listed as EVP, Chief Admin/Markets Offcr (previously President & COO) in SEC filings |
| Jun 8, 2018 | Brandy Burkhalter became EVP, Operations |
| Feb 5, 2018 | Jessica L. Blume became a director |
| Dec 14, 2017 | Mark J Brooks listed as EVP, Chief Information Officer (previously SVP, Chief Information Officer) in SEC filings |
| Dec 11, 2017 | Michael F Neidorff listed as Chairman & CEO (previously Chairman, President and CEO) in SEC filings |
| Dec 11, 2017 | Jesse N Hunter listed as EVP & Chief Strategy Officer (previously EVP, Products) in SEC filings |
| Dec 11, 2017 | Cynthia J Brinkley listed as President & COO (previously EVP, Global Corp Development) in SEC filings |
| Dec 13, 2016 | Jeffrey A. Schwaneke listed as EVP, CFO (previously SVP, Corp. Controller & CAO) in SEC filings |
| Nov 21, 2016 | Christopher D Bowers first listed as EVP, Markets in an SEC filing |
Not reported recently (21)
- Katie Casso · Last reported as Corporate Controller & CAO in an SEC filing dated Mar 17, 2026
- David P Thomas · Last reported as CEO, Markets and Medicaid in an SEC filing dated Dec 19, 2023
- William L Trubeck · Last reported as a director in an SEC filing dated Apr 4, 2023
- Richard A GEPHARDT · Last reported as a director in an SEC filing dated Feb 14, 2023
- Mark J Brooks · Last reported as EVP, Chief Information Officer in an SEC filing dated Sep 20, 2022
- Colin A Toney · Last reported as EVP, Mergers & Acquisitions in an SEC filing dated Sep 20, 2022
- Shannon Bagley · Last reported as EVP, Chief Admin. Officer in an SEC filing dated Aug 18, 2022
- Orlando Ayala · Last reported as a director in an SEC filing dated Apr 28, 2022
- Brandy Burkhalter · Last reported as EVP in an SEC filing dated Mar 28, 2022
- Michael F Neidorff · Last reported as a director in an SEC filing dated Feb 14, 2022
- Robert K Ditmore · Last reported as a director in an SEC filing dated Jan 4, 2022
- John R Roberts · Last reported as a director in an SEC filing dated Jan 4, 2022
- Tommy G Thompson · Last reported as a director in an SEC filing dated Jan 4, 2022
- David L Steward · Last reported as a director in an SEC filing dated Oct 4, 2021
- Jeffrey A. Schwaneke · Last reported as EVP, CFO in an SEC filing dated May 11, 2021
- Christopher R Isaak · Last reported as SVP, Corporate Controller, CAO in an SEC filing dated Dec 17, 2020
- Keith H Williamson · Last reported as EVP, Secr. & General Counsel in an SEC filing dated Feb 6, 2020
- Christopher D Bowers · Last reported as EVP, Markets in an SEC filing dated Jul 23, 2019
- Cynthia J Brinkley · Last reported as EVP, Chief Admin/Markets Offcr in an SEC filing dated Feb 7, 2019
- Carol Goldman · Last reported as Exec VP Chief Admin Officer in an SEC filing dated Feb 13, 2017
- Kenneth Rone Baldwin · Last reported as EVP, Markets in an SEC filing dated Dec 15, 2016
Compiled from SEC filings by the company and its directors and officers. Dates are as stated in those filings. Where no filing says when someone left, we show the last filing that listed them.
CNC Proposed Insider Sales (Form 144)
Latest: 2026-08-26
? Form 144 Guide
Last 30d:
0 filings
· Last 90d:
4 filings
· $16.5M notice value
· 2 unique filers
What is Form 144? A notice of intent to sell restricted or control stock under Rule 144. Affiliates (officers, directors, 10%+ owners) and holders of restricted shares must file Form 144 when planning to sell more than 5,000 shares or $50,000 in any 3-month rolling window.
How it relates to Form 4: Form 144 is filed before the trade (up to 90 days in advance); Form 4 is filed within 2 business days after the trade executes. Not every Form 144 results in a sale — the filer may cancel or delay. Look for the corresponding Form 4 on the Insider Activity card to confirm a sale actually happened.
10b5-1 plans: Trades made under a pre-scheduled Rule 10b5-1 plan are not discretionary — they execute automatically on dates set months earlier, regardless of news. High 10b5-1 percentages mean less per-filing signal value, though cumulative selling volume still matters.
"Notice value": Aggregate market value the filer wrote into the Form 144 — i.e. the size of the planned sale, not necessarily the executed dollars. An amended notice (Form 144/A) replaces the original it amends, and cancelled notices are dropped, so neither is double-counted above. A filed value that is clearly inconsistent with the share count at the stock's price (a filer typo) shows as a dash and is left out of the totals.
Source & freshness: Sourced from public Form 144 filings. Refreshed daily; new filings typically appear here the morning after they are filed.
Top 90-day filers:
Burdick Kenneth A (2, $9.6M) · KOSTER CHRISTOPHER (2, $6.9M)
| Filed | Filer | Role | Shares | Notice Value | Planned Sale | Broker | Plan | Link |
|---|---|---|---|---|---|---|---|---|
| 2026-08-26 | Burdick Kenneth A | Former Director | 43,600 | $2.83M | 2026-08-26 | Fidelity Brokerage Services LLC | — | EDGAR |
| 2026-08-26 | KOSTER CHRISTOPHER | Officer | 56,500 | $3.78M | 2026-08-26 | Fidelity Brokerage Services LLC | — | EDGAR |
| 2026-08-18 | KOSTER CHRISTOPHER | Officer | 47,603 | $3.11M | 2026-08-18 | Fidelity Brokerage Services LLC | — | EDGAR |
| 2026-08-05 | Burdick Kenneth A | Former Director | 100,000 | $6.82M | 2026-08-05 | Fidelity Brokerage Services LLC | — | EDGAR |
| 2026-06-10 | Burdick Kenneth A | Director | 80,000 | $5.16M | 2026-06-10 | Fidelity Brokerage Services LLC | — | EDGAR |
| 2025-12-04 | Burdick Kenneth A | Director | 32,796 | $1.28M | 2025-12-04 | Fidelity Brokerage Services LLC | — | EDGAR |
| 2025-12-03 | Burdick Kenneth A | Director | 33,211 | $1.30M | 2025-12-03 | Fidelity Brokerage Services LLC | — | EDGAR |
| 2025-10-15 | Wayne S DeVeydt | Director | 5,489 | $196.7K | 2025-10-15 | Merrill Lynch | — | EDGAR |
| 2025-09-09 | DeVeydt Wayne S | Director | 10,775 | $314.5K | 2025-09-09 | Merrill | — | EDGAR |
| 2025-03-21 | FASOLA KENNETH J | Officer | 8,500 | $502.0K | 2025-03-21 | Fidelity Brokerage Services LLC | — | EDGAR |
Notice value is the aggregate market value the filer states they intend to sell — not a confirmed transaction. Compare to Insider Activity (Form 4) to see which planned sales actually executed. Market-wide feed: Planned sales (Form 144).
Recent SEC Filings
Latest: 2026-05-15
Current reports — material events the company must disclose within 4 business days (earnings releases, M&A, executive changes, etc.).
| Filing Date | Accession | Link |
|---|---|---|
| 2026-05-15 | 0001071739-26-000117 | EDGAR |
| 2026-04-28 | 0001071739-26-000099 | EDGAR |
| 2026-03-24 | 0001071739-26-000070 | EDGAR |
| 2026-03-10 | 0001071739-26-000056 | EDGAR |
| 2026-02-23 | 0001071739-26-000052 | EDGAR |
| 2026-02-06 | 0001071739-26-000031 | EDGAR |
| 2025-11-10 | 0001071739-25-000188 | EDGAR |
| 2025-10-29 | 0001071739-25-000185 | EDGAR |
| 2025-09-11 | 0001071739-25-000168 | EDGAR |
| 2025-08-15 | 0001071739-25-000162 | EDGAR |
Annual report — audited financial statements, MD&A, risk factors. Filed 60–90 days after fiscal year-end.
| Filing Date | Accession | Link |
|---|---|---|
| 2026-02-17 | 0001071739-26-000049 | EDGAR |
| 2025-02-18 | 0001071739-25-000027 | EDGAR |
| 2024-02-20 | 0001071739-24-000037 | EDGAR |
| 2023-02-21 | 0001071739-23-000047 | EDGAR |
| 2022-02-22 | 0001071739-22-000071 | EDGAR |
| 2021-02-22 | 0001071739-21-000039 | EDGAR |
| 2020-02-18 | 0001071739-20-000060 | EDGAR |
| 2019-02-19 | 0001071739-19-000032 | EDGAR |
Quarterly report — unaudited financials and MD&A. Filed 40–45 days after each of the first three fiscal quarters.
| Filing Date | Accession | Link |
|---|---|---|
| 2026-04-28 | 0001071739-26-000098 | EDGAR |
| 2025-10-29 | 0001071739-25-000183 | EDGAR |
| 2025-07-25 | 0001071739-25-000150 | EDGAR |
| 2025-04-25 | 0001071739-25-000086 | EDGAR |
| 2024-10-25 | 0001071739-24-000200 | EDGAR |
| 2024-07-26 | 0001071739-24-000157 | EDGAR |
| 2024-04-26 | 0001071739-24-000097 | EDGAR |
| 2023-10-24 | 0001071739-23-000209 | EDGAR |
| 2023-07-28 | 0001071739-23-000183 | EDGAR |
| 2023-04-25 | 0001071739-23-000116 | EDGAR |
ETF Holders
299 ETFs hold CNC
25 shown · $5.68B total exposure · 0.09% AUM-weighted avg weight
| # | ETF | Provider | Weight | $ Exposure | ETF AUM | As Of |
|---|---|---|---|---|---|---|
| 1 | VTI Vanguard Morningstar Total Stock Market ETF | Vanguard | 0.04% | $973.0M | — | 2026-09-30 |
| 2 | VOO Vanguard S&P 500 ETF | Vanguard | 0.05% | $806.2M | — | 2026-09-30 |
| 3 | IVV iShares Core S&P 500 ETF | iShares (BlackRock) | 0.05% | $465.0M | $890.4B | 2026-10-20 |
| 4 | SPY State Street® SPDR® S&P 500® ETF Trust | SPDR (State Street) | 0.05% | $430.5M | $818.4B | 2026-10-20 |
| 5 | VB Vanguard Morningstar Small-Cap ETF | Vanguard | 0.19% | $345.3M | — | 2026-09-30 |
| 6 | VO Vanguard Morningstar Mid-Cap ETF | Vanguard | 0.15% | $328.6M | — | 2026-09-30 |
| 7 | XLV State Street® Health Care Select Sector SPDR® ETF | SPDR (State Street) | 0.54% | $255.0M | $47.5B | 2026-10-20 |
| 8 | VBR Vanguard Morningstar Small-Cap Value ETF | Vanguard | 0.35% | $224.8M | — | 2026-09-30 |
| 9 | RSP Invesco S&P 500 Equal Weight ETF | Invesco | 0.22% | $217.0M | — | 2026-10-20 |
| 10 | VFLO VictoryShares Free Cash Flow ETF | Nport | 2.16% | $167.6M | — | 2026-06-30 |
| 11 | AVLV Avantis U.S. Large Cap Value ETF | Avantis | 0.70% | $156.1M | $22.3B | 2026-10-20 |
| 12 | IWR iShares Russell Mid-Cap ETF | iShares (BlackRock) | 0.26% | $146.3M | $57.3B | 2026-10-20 |
| 13 | VTV Vanguard Morningstar Value ETF | Vanguard | 0.06% | $146.2M | — | 2026-09-30 |
| 14 | USMV iShares MSCI USA Min Vol Factor ETF | iShares (BlackRock) | 0.48% | $116.1M | $24.0B | 2026-10-20 |
| 15 | RWL Invesco S&P 500 Revenue ETF | Invesco | 1.10% | $113.8M | — | 2026-10-20 |
| 16 | FNDX Schwab Fundamental U.S. Large Company ETF | Nport | 0.43% | $108.4M | — | 2026-05-31 |
| 17 | SPYM State Street® SPDR® Portfolio S&P 500® ETF | SPDR (State Street) | 0.05% | $96.4M | $183.5B | 2026-10-20 |
| 18 | VOE Vanguard Morningstar Mid-Cap Value ETF | Vanguard | 0.26% | $95.8M | — | 2026-09-30 |
| 19 | VHT Vanguard Health Care ETF | Vanguard | 0.43% | $93.7M | — | 2026-09-30 |
| 20 | SCHM Schwab U.S. Mid-Cap ETF | Nport | 0.52% | $75.3M | — | 2026-05-31 |
| 21 | CGGO Capital Group Global Growth Equity ETF | Capitalgroup | 0.61% | $72.8M | $11.9B | 2026-10-20 |
| 22 | IWD iShares Russell 1000 Value ETF | iShares (BlackRock) | 0.09% | $71.8M | $84.5B | 2026-10-20 |
| 23 | IHF iShares U.S. Healthcare Providers ETF | iShares (BlackRock) | 4.26% | $59.1M | $1.4B | 2026-10-20 |
| 24 | IVE iShares S&P 500 Value ETF | iShares (BlackRock) | 0.12% | $57.9M | $50.4B | 2026-10-20 |
| 25 | SPMO Invesco S&P 500 Momentum ETF | Invesco | 0.24% | $52.3M | — | 2026-10-20 |
Fundamentals
Quarterly filings sourced from SEC 10-Q / 10-K reports. TTM tiles aggregate the most recent four quarters; bars show the last ~12 quarters oldest → newest.
Metrics
- Revenue — top-line sales. Look for consistent YoY growth; seasonal businesses need same-quarter comparisons (Q4 '24 vs Q4 '23).
- Net Income — bottom-line profit after all expenses. Can be volatile from one-time items; red bars = net loss.
- Diluted EPS — net income per share assuming options/converts are exercised. Direct input to the P/E ratio.
- Operating Cash Flow — cash generated from core operations, before capex and financing. Harder to manipulate than net income; growing OCF is a quality signal.
How to read the bars
- Sequential growth — quarter-over-quarter trend. Accelerating bars are a momentum signal.
- YoY growth — compare to the same quarter a year earlier to remove seasonality.
- Quality — OCF should roughly track Net Income over time. Large divergence (net income ≫ OCF) flags accruals risk.
- Margins — scan the bar ratios: Net Income / Revenue tells you margin trend without needing a separate chart.
TTM (trailing-twelve-month) smooths seasonality and is used for the P/E calculation. Filings appear 30–90 days after the period closes.
Trailing P/E
—
TTM Diluted EPS
$-13.14
TTM Revenue
$199.70B
TTM Net Income
$-6.44B
TTM Op. Cash Flow
$7.94B
Quarterly figures (12 quarters)
| Quarter | Period End | Revenue | Net Income | Diluted EPS | Op. Cash Flow |
|---|---|---|---|---|---|
| Q1 '26 | 2026-03-31 | $50.35B | $1.54B | $3.11 | $4.37B |
| Q4 '25 | 2025-12-31 | $50.09B | $-1.10B | $-2.24 | $437.00M |
| Q3 '25 | 2025-09-30 | $50.14B | $-6.63B | $-13.50 | $1.36B |
| Q2 '25 | 2025-06-30 | $49.11B | $-253.00M | $-0.51 | $1.78B |
| Q1 '25 | 2025-03-31 | $47.00B | $1.31B | $2.63 | $1.51B |
| Q4 '24 | 2024-12-31 | $41.15B | $283.00M | $0.62 | $-587.00M |
| Q3 '24 | 2024-09-30 | $42.45B | $713.00M | $1.36 | $-978.00M |
| Q2 '24 | 2024-06-30 | $40.30B | $1.15B | $2.16 | $2.17B |
| Q1 '24 | 2024-03-31 | $40.95B | $1.16B | $2.16 | $-456.00M |
| Q4 '23 | 2023-12-31 | $39.86B | $45.00M | $0.10 | $217.00M |
| Q3 '23 | 2023-09-30 | $38.26B | $469.00M | $0.87 | $1.02B |
| Q2 '23 | 2023-06-30 | $37.61B | $1.06B | $1.92 | $2.55B |
Q1 2026 • period ending 2026-03-31 • filed 2026-04-28
Valuation
Ratios derived from TTM financials and the current market price, sampled daily. History chart shows how expensive the stock is today relative to its own recent past.
Price Multiples
- P/E — price / TTM earnings. Rough market rule: 10–15 value, 15–25 market, >30 growth/premium. Negative when earnings are negative.
- P/B — price / book value. Useful for financials and asset-heavy names; meaningless for asset-light software.
- P/S — price / TTM revenue. Useful when earnings are negative or noisy (early-stage growth).
- EV/EBITDA — capital-structure-neutral. <10 cheap, 10–15 reasonable, >20 rich. Good for comparing across leverage profiles.
- EV/Sales — like P/S but accounts for debt + cash. Compare within sector.
Profitability & Yields
- ROE — return on equity. >15% strong, >25% exceptional. Caution: high leverage inflates ROE.
- ROA — return on assets. Leverage-neutral; >5% solid, >10% exceptional.
- Div Yield — annual dividend / price. Compare to 10Y Treasury; sustained yield >6% often signals distress.
- FCF Yield — free cash flow / market cap. >5% is attractive; negative means burning cash.
Balance Sheet
- Debt/Equity — leverage. <1 conservative, >2 aggressive. Sector-dependent (utilities naturally high, tech low).
- Current Ratio — short-term liquidity. >1.5 comfortable, <1 raises short-term solvency flags.
Reading the history chart
- Compare current level to the 3-year band: near the high end = relatively expensive; near the low = relatively cheap.
- Multiples expanding while earnings are flat = sentiment-driven rally.
- Multiples compressing while earnings grow = value coming from fundamentals.
P/E
—
P/B
1.61
P/S
0.17
EV/EBITDA
10.36
EV/Sales
0.15
ROE
-29.9%
ROA
-7.9%
Div Yield
0.00%
FCF Yield
22.92%
Debt/Equity
0.76
Current Ratio
—
Market Cap
$34.65B
as of 2026-10-21
Short Interest & Float
Regulatory short-interest reports publish on a bi-weekly settlement cadence; short-volume is reported daily by the trade-reporting facilities. Float is derived from insider-ownership filings.
Metric definitions
- Short Interest — total shares currently sold short as of the settlement date. Lags real time by ~8 business days.
- SI % of Float — short interest / free float. The key crowding metric.
- Days to Cover — short interest / avg daily volume. How many full trading days it would take shorts to buy back. High DTC + catalyst = squeeze fuel.
- Short Vol Ratio — today's short-sale volume / total volume. Intraday selling pressure proxy (not the same as short interest).
- Free Float — shares available for public trading (total shares minus insider / restricted).
- Float % — free float / shares outstanding. <50% = tightly held, more prone to squeezes.
How to read the signals
- SI % of Float < 5% — typical, no particular signal.
- 5–15% — elevated; watch for catalysts (earnings, guidance, macro).
- 15–30% — heavily shorted; tight-float names in this range have produced notable squeezes historically.
- >30% — extreme; borrow is likely expensive and squeeze risk is material.
- Days to Cover > 5 combined with high SI% amplifies squeeze potential.
History chart
- Trend matters more than level. Rapidly rising short interest often precedes negative catalysts or heavy hedging.
- A sudden drop in SI after a rally may indicate a squeeze in progress.
Short interest is reported mid-month and end-of-month; short volume is daily.
Short Interest
10.51M
SI % of Float
2.13%
Days to Cover
1.99
Short Vol Ratio
43.5%
Free Float
492.51M
Float %
99.7%
Short interest 2026-09-30 • Short volume 2026-10-21 • Float 2026-09-22